New Antibody Therapy 77A Enhances Immune Response Against Cancers

Researchers from The University of Texas MD Anderson Cancer Center have developed a promising new antibody therapy, known as 77A, which has shown potential in enhancing the immune response against various blood cancers and solid tumors. This innovative approach targets a protein called HSP70 that is often overproduced in tumors, allowing them to evade the immune system. The findings were presented on December 6, 2025, at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

Led by Jun Wei, M.D., Ph.D., an assistant professor of Lymphoma & Myeloma, and Robert Z. Orlowski, M.D., Ph.D., a professor in the same department, the research indicates that 77A has the ability to reprogram immune cells, enabling a more effective attack on multiple cancer types, including myeloma and lymphoma. The results of this preclinical study suggest a new direction for immunotherapy.

Mechanism of Action for 77A

The mechanism by which 77A operates involves its targeting of HSP70, a heat shock protein associated with immune evasion in tumors. By inhibiting HSP70, 77A activates T cells and natural killer (NK) cells, which are crucial components of the immune system. In laboratory models, the therapy enhanced the activity of these immune cells, improving their ability to identify and destroy cancer cells.

In addition to its standalone effects, 77A demonstrated synergistic benefits when combined with existing treatments like chemotherapy, radiation therapy, and immune checkpoint inhibitors. Furthermore, preliminary tests showed that it might enhance immune responses in healthy human donors, indicating its potential applicability in clinical settings.

Future Directions for Clinical Trials

The implications of these findings extend towards future clinical trials. The research team is optimistic about advancing a humanized version of the 77A antibody into clinical studies, which could open new therapeutic avenues for patients battling various cancers. “These results give us confidence that 77A could become a versatile immunotherapy,” said Orlowski. “Our next step is to evaluate its potential in patients across multiple cancer types.”

This study received support from Blood Cancer United (formerly known as the Leukemia & Lymphoma Society), reinforcing its credibility. A complete list of collaborating authors and their disclosures can be found with the abstract of the study. As the research progresses, 77A could represent a significant advancement in cancer treatment, particularly for those who have developed resistance to current therapies.

The findings of this study highlight a crucial step forward in the fight against cancer, offering new hope for patients and paving the way for innovative treatment strategies.